Anti-TNF alpha antibody [EPR22598-212]
- KO Validated
- RabMAb
- Recombinant
- Lab Essentials
- 20ul selling size
- What is this?
Be the first to review this product! Submit a review
|
(15 Publications)
Rabbit Recombinant Monoclonal TNF alpha antibody. Suitable for IP, WB, Flow Cyt (Intra) and reacts with Human samples. Cited in 15 publications.
View Alternative Names
TNFA, TNFSF2, TNF, Tumor necrosis factor, Cachectin, TNF-alpha, Tumor necrosis factor ligand superfamily member 2, TNF-a
- Flow Cyt (Intra)
Lab
Flow Cytometry (Intracellular) - Anti-TNF alpha antibody [EPR22598-212] (AB255275)
Intracellular flow cytometric analysis of2% paraformaldehyde-fixed, 0.1% Tween 20 permeabilized Human peripheral blood mononuclear cell (PBMC) treated with 50ng/ml PMA, 250ng/ml ionomycin and 300ng/ml Brefeldin A for 16h, labeling TNF alpha with ab255275 at 1/700 dilution (Right) compared with Recombinant Rabbit IgG, monoclonal [EPR25A] - Isotype Control (ab172730) (Left).
Goat Anti-Rabbit IgG Fc (Alexa Fluor® 488) preadsorbed (ab150097), at 1/5000 dilution was used as the secondary antibody.
Cells were surface stained with anti-CD3 conjugated to Alexa Fluor® 647. Then fixed with 2% PFA for 10min and intracellularly stained with rabbit IgG (Left) or ab236836 (Right).
- IP
Supplier Data
Immunoprecipitation - Anti-TNF alpha antibody [EPR22598-212] (AB255275)
TNF alpha was immunoprecipitated from 0.35 mg of THP-1 (human monocytic leukemia cell line) (treated with 80nM TPA overnight, replaced the culture medium with 100 ng/ml Lipopolysaccharides (LPS) for 6 hours with addition of 300ng/ml Brefeldin A (BFA) for the last 3 hours) whole cell lysate with ab255275 at 1/30 dilution. Western blot was performed from the immunoprecipitate using ab255275 at 1/1000 dilution. VeriBlot for IP Detection Reagent (HRP) (ab131366), was used as secondary antibody at 1/5000 dilution.
Lane 1 : THP-1 (treated as above) whole cell lysate 10 μg (Input).
Lane 2 : ab255275 IP in THP-1 (treated as avove) whole cell lysate.
Lane 3 : Rabbit monoclonal IgG (ab172730) instead of ab255275 in THP-1 (treated as above) whole cell lysate.
Blocking and dilution buffer and concentration : 5% NFDM/TBST.
Exposure time : 15 seconds.
All lanes:
Immunoprecipitation - Anti-TNF alpha antibody [EPR22598-212] (ab255275)
Predicted band size: 25 kDa
Observed band size: 25 kDa
false
- WB
Lab
Western blot - Anti-TNF alpha antibody [EPR22598-212] (AB255275)
Lanes 1 - 6 : Merged signal (red and green). Green - ab255275 observed at 26 kDa. Red - loading control ab7291 (Mouse anti-Alpha Tubulin [DM1A]) observed at 55 kDa.
ab255275 was shown to react with TNF alpha in THP-1 wild-type cells in Western blot with loss of signal observed in TNF knockout sample. Wild-type and TNF knockout THP-1 cell lysates were subjected to SDS-PAGE. Membranes were blocked in fluorescent western blot (TBS-based) blocking solution before incubation with ab255275 and ab7291 (Mouse anti-Alpha Tubulin [DM1A]) overnight at 4 °C at a 1 in 1000 dilution and a 1 in 20000 dilution respectively. Blots were incubated with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preabsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preabsorbed (ab216776) secondary antibodies at 1 in 20000 dilution for 1 h at room temperature before imaging.
All lanes:
Western blot - Anti-TNF alpha antibody [EPR22598-212] (ab255275) at 1/1000 dilution
Lane 1:
Wild-type THP-1 Brefeldin A (<a href='/en-us/products/biochemicals/brefeldin-a-inhibitor-of-adp-ribosylation-factor-ab120299'>ab120299</a>) treated (5 µg/ml, 4 h) cell lysate at 30 µg
Lane 2:
Wild-type THP-1 LPS treated (100 ng/ml, 16 h) and Brefeldin A (<a href='/en-us/products/biochemicals/brefeldin-a-inhibitor-of-adp-ribosylation-factor-ab120299'>ab120299</a>) treated (5 µg/ml, 4 h) cell lysate at 30 µg
Lane 2:
Western blot - Human TNF knockout THP-1 cell line (<a href='/en-us/products/cell-lines/human-tnf-knockout-thp-1-cell-line-ab273761'>ab273761</a>)
Lane 3:
TNF alpha knockout THP-1 Brefeldin A (<a href='/en-us/products/biochemicals/brefeldin-a-inhibitor-of-adp-ribosylation-factor-ab120299'>ab120299</a>) treated (5 µg/ml, 4 h) cell lysate at 30 µg
Lane 4:
TNF alpha knockout THP-1 LPS treated (100 ng/ml, 16 h) and Brefeldin A (<a href='/en-us/products/biochemicals/brefeldin-a-inhibitor-of-adp-ribosylation-factor-ab120299'>ab120299</a>) treated (5 µg/ml, 4 h) cell lysate at 30 µg
Lane 5:
U937 PMA treated (10 mM, 2 days) plus 16 h no treatment and Brefeldin A (<a href='/en-us/products/biochemicals/brefeldin-a-inhibitor-of-adp-ribosylation-factor-ab120299'>ab120299</a>) treated (5 µg/ml, 4 h) cell lysate at 30 µg
Lane 6:
U937 PMA treated (10 mM, 2 days) and LPS treated (1 µg/ml, 16 h) plus Brefeldin A (<a href='/en-us/products/biochemicals/brefeldin-a-inhibitor-of-adp-ribosylation-factor-ab120299'>ab120299</a>) treated (5 µg/ml, 4 h) cell lysate at 30 µg
Predicted band size: 25 kDa
Observed band size: 26 kDa
false
- WB
Supplier Data
Western blot - Anti-TNF alpha antibody [EPR22598-212] (AB255275)
Blocking and dilution buffer : 5% NFDM/TBST.
The expression profile observed is consistent with what has been described in the literature (PMID : 9657756).
All lanes:
Western blot - Anti-TNF alpha antibody [EPR22598-212] (ab255275) at 1/1000 dilution
Lane 1:
THP-1 (human monocytic leukemia cell line) (treated with 80nM 12-O-Tetradecanoylphorbol-13-acetate (TPA) overnight) whole cell lysate at 20 µg
Lane 2:
THP-1 (treated with 80nM TPA overnight, replaced the culture medium with 100 ng/ml lipopolysaccharides (LPS) for 6 hours with addition of 300ng/ml Brefeldin A (BFA) for the last 3 hours) whole cell lysate at 20 µg
Secondary
All lanes:
Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/100000 dilution
Predicted band size: 25 kDa
Observed band size: 25 kDa
false
Exposure time: 3min
Related conjugates and formulations (2)
-
Anti-TNF alpha antibody [EPR22598-212] - BSA and Azide free
-
665 Alexa Fluor® 647
Alexa Fluor® 647 Anti-TNF alpha antibody [EPR22598-212]
Reactivity data
Product details
Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free batch production
For more information, read more on recombinant antibodies.
Properties and storage information
Form
Purification technique
Storage buffer
Shipped at conditions
Appropriate short-term storage duration
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Aliquoting information
Storage information
Product protocols
- Visit the General protocols
- Visit the Troubleshooting
Target data
Publications (15)
Recent publications for all applications. Explore the full list and refine your search
MedComm 6:e70311 PubMed40761479
2025
Applications
Unspecified application
Species
Unspecified reactive species
Food science & nutrition 13:e70688 PubMed40755501
2025
Applications
Unspecified application
Species
Unspecified reactive species
Obesity facts 17:24-36 PubMed37820603
2023
Applications
Unspecified application
Species
Unspecified reactive species
ImmunoHorizons 7:71-80 PubMed36645851
2023
Applications
Unspecified application
Species
Unspecified reactive species
Journal of neuroinflammation 19:312 PubMed36566220
2022
Applications
Unspecified application
Species
Unspecified reactive species
Molecular medicine reports 26: PubMed36004465
2022
Applications
Unspecified application
Species
Unspecified reactive species
Molecular medicine reports 26: PubMed35856414
2022
Applications
Unspecified application
Species
Unspecified reactive species
Bioengineered 13:12275-12288 PubMed35603354
2022
Applications
Unspecified application
Species
Unspecified reactive species
Frontiers in cellular and infection microbiology 12:851197 PubMed35651754
2022
Applications
Unspecified application
Species
Unspecified reactive species
Frontiers in microbiology 13:861734 PubMed35359726
2022
Applications
Unspecified application
Species
Unspecified reactive species
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com